This is the ultimate question that integrates all facets of the study. The hypothesis is that a "catastrophic" immune response triggers a cascade of multi-system dysfunction, preventing recovery. MAESTRO's "leave no stone unturned" approach is designed to map this entire cascade.

• Investigating Neuroinflammation and "Brain Fog":

  • Objective Brain Function Tests: We use WAVi (EEG) to measure the brain's electrical activity and processing speed and RightEye (infrared eye-tracking) to assess neurological function and oculomotor control. These tools provide objective, quantitative evidence to validate patient reports of cognitive dysfunction. Our preliminary data has already linked reductions in protective proteins like PON1 and increases in inflammatory markers like Trypsin 2 with slower reaction times on these tests, providing a direct bridge between biology and symptoms.

  • Validated Cognitive Surveys: The PROMIS Cognitive Function and Brain Injury Vision Symptom Survey (BIVSS) questionnaires provide standardized scores for the subjective experience of brain fog and visual disturbances.

• Investigating Autonomic, Vascular, and Endothelial Dysfunction:

  • Functional Tests: The NASA 10-Minute Lean Test directly assesses for autonomic dysfunction like POTS, while Capillaroscopy provides a non-invasive window into the health of the microvasculature.

  • Profiling: Blood samples are analyzed for clotting factors, platelets, and complement cascade proteins to investigate hypercoagulation and endothelial dysfunction.

  • Surveys: The COMPASS 31 survey directly quantifies autonomic symptoms. Investigating Barrier Permeability (Gut, Blood-Brain):

  • Profiling: Saliva samples are analyzed for markers like salivary hemoglobin to assess gut permeability. Blood samples are analyzed for markers of blood-brain barrier integrity, such as S100B, to investigate if systemic inflammation is affecting the central nervous system

• Investigating Mitochondrial & Metabolic Dysfunction:

  • Profiling: Metabolomics (Nightingale) maps metabolic pathways, WGS covers mitochondrial gene profiling, and proteomics (Olink) can be cross-referenced with mitochondrial protein databases (Mitocarta) to identify signatures of energy dysfunction.

  • Surveys: The profound fatigue is quantified using FSS-9, VAFS, and DSQ-PEM.

• Investigating Connective Tissue Breakdown:

  • Tests: In-person Hypermobility Assessments (e.g., Beighton score) provide an objective measure of joint and connective tissue integrity.

  • Profiling: Blood and urine can be analyzed for collagen breakdown markers like hydroxyproline and matrix metalloproteinases (MMPs).

  • Surveys: The Past Medical History survey asks about EDS/HSD diagnoses and symptoms like joint subluxations.

• Investigating Sleep Dysfunction:

  • Longitudinal Monitoring: The Evie Ring, a smart wearable device provided to all participants, continuously tracks key metrics like sleep stages, duration, heart rate, heart rate variability (HRV), and blood oxygen levels (SpO2). This provides an objective, real-world picture of sleep quality and its disruption.

  • Correlating with Symptoms and Biology: This longitudinal sleep data can be directly correlated with daily symptom logs and the deep biological data collected during the in-person visit. This allows us to ask critical questions: Does poor sleep quality correlate with lower levels of immune cell turnover or with higher levels of certain inflammatory markers? Do specific sleep patterns predict the severity of next-day fatigue or "brain fog" or pain levels?

  • Subjective Sleep Data: The THRIVE and Past Medical History surveys capture participants' subjective experience of sleep, including difficulty falling asleep, staying asleep, and feeling unrefreshed. Comparing this self-reported data with the objective Evie Ring data provides a more complete understanding of sleep disturbances.

• Investigating Underlying Triggers (Persistent Infection or a Dysbiotic State?):

  • Deep Pathogen and Microbiome Profiling: Using metagenomic analysis on samples from multiple body sites (blood, saliva, throat, vaginal, and rectal swabs), we can search for evidence of persistent pathogens or an imbalanced microbiome (dysbiosis) that could be driving chronic immune activation. Deep metagenomic sequencing (30X WGS) and targeted ddPCR on samples from multiple sample types search for pathogens like Borrelia, Bartonella, Babesia, herpesviruses (EBV, CMV), and fungi. This provides a comprehensive view of the "pathogen landscape" and can help investigate if persistent infection, latent virus reactivation, or an imbalanced microbiome is driving chronic immune activation.  

Multi-Hit Hypothesis: The extensive Past Medical History and Current Symptoms surveys allow us to document a lifetime of potential triggers—other infections, accidents, surgeries, mold exposure, or major life stressors—that could contribute to a cumulative physiological burden, pushing a susceptible individual into a state of chronic illness. 

Our group recognizes that sex is a critical and often overlooked variable in chronic disease. MAESTRO is uniquely positioned to investigate the roles of sex hormones and gynecological health in disease risk and manifestation.

• How Sample Profiling Provides the Answer:

  • Steroidomics (TMIC): This analysis directly measures the levels of dozens of steroid hormones, including testosterone, estrogen, and progesterone, from blood samples. This allows us to move beyond sex as a simple category and ask more nuanced questions. For example, do women with chronic Lyme who have low testosterone or high progesterone levels show a more inflammatory immune profile?

  • Vaginal Swabs: The collection of both wet and dry vaginal swabs is a pioneering aspect of the study. It allows for analysis of the local mucosal immune environment, microbiome, and pathogen persistence within the female reproductive tract. This directly tests the hypothesis that these infections can cause or exacerbate "gynepathologies" like endometriosis, contributing to the overall disease burden in females.  

• How Surveys Provide the Answer:

  • Detailed Gynecological History: The Past Medical History survey includes an exhaustive section on obstetric and gynecological health, capturing diagnoses like endometriosis, PCOS, and adenomyosis. This allows us to investigate whether these conditions are predisposing risk factors.  

Menstrual Cycle Tracking: The COVID-19 and Current Symptoms surveys contain novel sections that ask participants to track how their chronic symptoms (like pain, fatigue, and brain fog) fluctuate with their menstrual cycle. This provides powerful data to link hormonal shifts directly to the lived experience of the illness. 

This question is the cornerstone of the study's mission to develop predictive diagnostics. The goal is to identify biological signatures that can predict, early in an infection, whether a person's immune response will successfully clear the pathogen and return to normal (protective) or become dysregulated and cause lasting harm (catastrophic).

• How Sample Profiling Provides the Answer:

  • High-Resolution Antibody Mapping (FLIP Technology): This is the study's key innovation. Instead of relying on standard diagnostics that measure only total IgG or IgM antibodies, MAESTRO uses a proprietary technology called FLIP (Flow-based Immune Profiling). By analyzing the full spectrum of antibody isotypes and subtypes (e.g., IgG1, IgG2, IgA, IgE) that bind to pathogens in blood and saliva, we can create a detailed "immune signature." The central hypothesis is that the ratio and quality of these antibodies—not just their presence—determines the outcome. For example, a protective response might be characterized by high levels of a specific IgG subtype, while a catastrophic response might be marked by an aberrant, allergic-type IgE response.  

  • Deep Proteomics (Olink & Legendplex): By measuring thousands of proteins, cytokines, and chemokines in the blood, we can identify the specific inflammatory pathways that are activated. This allows us to ask: Is a catastrophic response defined by persistently high levels of inflammatory markers like TNF-α or IL-6, or by specific "allergic-type" cytokines like IL-4 and IL-13.  

  • Metabolomics (Nightingale): These analyses provide a snapshot of the body's energy and metabolic state. This helps us investigate whether a catastrophic response involves profound mitochondrial dysfunction, leading to the debilitating fatigue that characterizes these illnesses.  

• How Surveys and Tests Provide Context:

  • Infection and Symptom Timelines: The detailed Tick Exposure and COVID-19 surveys establish a clear timeline from infection to the onset of chronic symptoms. This is critical for linking the biological signatures found at a specific timepoint to the ultimate clinical outcome.  

Quantifying the Outcome: Validated surveys like the FUNCAP27 (for post-exertional malaise) and COMPASS 31 (for autonomic dysfunction) provide quantitative scores for the severity of the illness. A participant with a severe PEM score whose blood sample shows a high IgE signature would provide strong evidence for an allergic-type catastrophic response.